Life Molecular Imaging Ltd., a subsidiary of South Africa’s Life Healthcare Group focused on PET radiopharmaceuticals, and St. Teresa’s Hospital, a private hospital in Hong Kong, announced the launch of Neuraceq (florbetaben (18F)) in Hong Kong this month. This marks a significant advancement in the diagnosis and management of Alzheimer’s disease (AD) and other cognitive impairments in the region.
Product Overview
Neuraceq is an FDA-approved radioactive diagnostic agent used to detect amyloid plaques in the brains of adult patients with cognitive impairment being evaluated for AD and other causes of cognitive decline. Its clinical applications are twofold: routine diagnosis and patient characterization for treatment eligibility with anti-amyloid drugs or clinical trial enrollment.
Market and Clinical Significance
The launch of Neuraceq in Hong Kong provides healthcare professionals with a powerful tool to support the accurate diagnosis of AD and guide treatment decisions. It also facilitates the inclusion of patients in clinical trials for neurodegenerative diseases, accelerating research and development in this field.
Mainland China Developments
In mainland China, Beijing-based Sinotau Pharmaceutical Group obtained marketing approval for its generic version of Neuraceq in September 2023, reflecting growing recognition of the importance of amyloid detection in AD management.-Fineline Info & Tech
Leave a Reply